DAFNA Capital Management LLC — 13F Holdings & Portfolio
CIK 1389933 · latest 13F-HR filed 2026-08-14
DAFNA Capital Management LLC manages $524.4M in 13F-reported U.S. long-equity assets across 88 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (20.09%), XBI (5.93%), CMPS (5.43%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions, exited 12, added to 36, and trimmed 22.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 1400
LOS ANGELES, CA 90024
$524.4M
Long-equity book
88
Distinct positions
2026-06-30
Filed 2026-08-14
+17 / −12 / ↑36 / ↓22
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- REVOLUTION MEDICINES INC$48.9M +86.6%
- COMPASS PATHWAYS PLC$15.1M +112.8%
- DENALI THERAPEUTICS INC$12.9M +210.8%
- NEKTAR THERAPEUTICS$10.3M +87.0%
- INSULET CORP$7.1M +313.0%
Top Trims
- SPDR S&P BIOTECH ETF-$9.6M -23.6%
- BIOHAVEN LTD-$5.1M -71.4%
- MBX BIOSCIENCES INC-$4.6M -87.6%
- LARIMAR THERAPEUTICS INC-$3.0M -32.9%
- ISHARES NASDAQ BIOTECH INDX-$2.4M -22.7%
New Positions
- ASCENDIS PHARMA A/S$12.9M
- KYMERA THERAPEUTICS INC$3.1M
- ADLAI NORTYE LTD$2.8M
- NERVGEN PHARMA CORP$2.2M
- ATRIUM THERAPEUTICS INC$1.7M
Exited Positions
- DAY ONE BIOPHARMACEUTICALS I$21.0M
- ASCENDIS PHARMA A/S$5.9M
- KALVISTA PHARMACEUTICALS INC$5.4M
- ASCENDIS PHARMA A/S$5.3M
- FULCRUM THERAPEUTICS INC$1.6M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $105.4M | 20.09% | 562,630 | SH |
| 2 | SPDR S&P BIOTECH ETF | XBI | 78464A870 | $31.1M | 5.93% | 196,505 | SH |
| 3 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $28.5M | 5.43% | 2,011,952 | SH |
| 4 | STEREOTAXIS INC | STXS | 85916J409 | $23.5M | 4.49% | 13,680,554 | SH |
| 5 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $22.2M | 4.24% | 318,380 | SH |
| 6 | DENALI THERAPEUTICS INC | DNLI | 24823R105 | $19.0M | 3.62% | 739,014 | SH |
| 7 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $18.5M | 3.53% | 497,240 | SH |
| 8 | ATRICURE INC | ATRC | 04963C209 | $16.7M | 3.19% | 597,431 | SH |
| 9 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $15.1M | 2.89% | 250,772 | SH |
| 10 | CYTOKINETICS INC | CYTK | 23282W605 | $14.7M | 2.79% | 171,998 | SH |
| 11 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $13.6M | 2.60% | 441,829 | SH |
| 12 | ASCENDIS PHARMA A/S | ASND | K08588103 | $12.9M | 2.47% | 48,469 | SH |
| 13 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $9.7M | 1.86% | 57,769 | SH |
| 14 | AXOGEN INC | AXGN | 05463X106 | $9.7M | 1.84% | 208,960 | SH |
| 15 | INSULET CORP | PODD | 45784P101 | $9.4M | 1.80% | 61,870 | SH |
| 16 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $9.2M | 1.76% | 226,819 | SH |
| 17 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $8.5M | 1.61% | 284,955 | SH |
| 18 | ISHARES NASDAQ BIOTECH INDX | IBB | 464287556 | $8.1M | 1.54% | 42,595 | SH |
| 19 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $7.3M | 1.40% | 335,255 | SH |
| 20 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $6.1M | 1.17% | 171,006 | SH |
| 21 | LARIMAR THERAPEUTICS INC | LRMR | 517125100 | $6.1M | 1.17% | 2,008,164 | SH |
| 22 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $5.9M | 1.12% | 2,400,458 | SH |
| 23 | DEXCOM INC | DXCM | 252131107 | $5.8M | 1.11% | 86,279 | SH |
| 24 | IMMUNOVANT INC | IMVT | 45258J102 | $5.8M | 1.10% | 149,524 | SH |
| 25 | INOGEN INC | INGN | 45780L104 | $5.5M | 1.04% | 845,179 | SH |
| 26 | TANDEM DIABETES CARE INC | TNDM | 875372203 | $5.4M | 1.02% | 355,208 | SH |
| 27 | ALKERMES PLC | ALKS | G01767105 | $5.3M | 1.01% | 101,266 | SH |
| 28 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $4.3M | 0.82% | 130,875 | SH |
| 29 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $4.2M | 0.79% | 2,000,000 | SH |
| 30 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $4.0M | 0.76% | 400,248 | SH |
| 31 | LAKEFRONT BIOTHERAPEUTICS NV | LKFT | 36315X101 | $3.9M | 0.74% | 130,175 | SH |
| 32 | ORTHOPEDIATRICS CORP | KIDS | 68752L100 | $3.6M | 0.69% | 189,130 | SH |
| 33 | CYBIN INC | HELP | 23256X407 | $3.4M | 0.65% | 514,061 | SH |
| 34 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $3.1M | 0.60% | 75,000 | SH |
| 35 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $3.1M | 0.59% | 27,000 | SH |
| 36 | PROQR THERAPEUTICS NV | PRQR | N71542109 | $2.8M | 0.54% | 1,530,361 | SH |
| 37 | NEUROGENE INC | NGNE | 64135M105 | $2.8M | 0.53% | 89,032 | SH |
| 38 | ADLAI NORTYE LTD | ANL | 00704R109 | $2.8M | 0.53% | 239,553 | SH |
| 39 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $2.7M | 0.52% | 120,000 | SH |
| 40 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $2.7M | 0.51% | 645,915 | SH |
| 41 | CELLDEX THERAPEUTICS INC | CLDX | 15117B202 | $2.5M | 0.49% | 68,518 | SH |
| 42 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $2.5M | 0.48% | 46,500 | SH |
| 43 | ALIGN TECHNOLOGY INC | ALGN | 016255101 | $2.4M | 0.45% | 14,000 | SH |
| 44 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $2.3M | 0.44% | 59,516 | SH |
| 45 | NERVGEN PHARMA CORP | NGEN | 64082X203 | $2.2M | 0.41% | 1,050,000 | SH |
| 46 | BIOHAVEN LTD | BHVN | G1110E107 | $2.0M | 0.39% | 137,593 | SH |
| 47 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $1.9M | 0.37% | 65,000 | SH |
| 48 | ALECTOR INC | ALEC | 014442107 | $1.8M | 0.35% | 908,351 | SH |
| 49 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $1.8M | 0.33% | 377,059 | SH |
| 50 | PROFOUND MEDICAL CORP | PROF | 74319B502 | $1.7M | 0.33% | 260,360 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $524.4M | 88 | 0001389933-26-000006 |
| 2026-03-31 | 2026-05-15 | $439.6M | 83 | 0001389933-26-000004 |
| 2025-12-31 | 2026-02-17 | $430.5M | 77 | 0001389933-26-000002 |
| 2025-09-30 | 2025-11-14 | $404.8M | 75 | 0001389933-25-000008 |